Model results suggest that adding canagliflozin 100 mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England (Diabetes Therapy)
Diabetes News
Category: Treatment
Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps
Changes in diabetes-related protocols and new technology can be deployed in the inpatient setting to potentially improve healthcare worker and patient safety; however, one must weigh the risks and benefits of implementation during a pandemic (Current Diabetes Reports)
Integrated personalized diabetes management goes Europe: A multi-disciplinary approach to innovating type 2 diabetes care in Europe
Building on an iterative six-step disease management process that leverages feedback loops and utilizes commodity digital tools, the PDM-ProValue study program demonstrated that integrated personalized diabetes management, or iPDM, can improve the standard of care for persons living with diabetes in a sustainable way (Primary Care Diabetes)
Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial
FMT halts decline in endogenous insulin production in recently diagnosed patients with T1D in 12 months after disease onset. Several microbiota-derived plasma metabolites and bacterial strains were linked to preserved residual beta cell function. This study provides insight into the role of the intestinal gut microbiome in T1D(BMC Gut)
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Central to our manifesto is a shift from linear treatment algorithms based on HbA1c target setting to parallel, independent considerations of atherosclerotic cardiovascular disease, heart failure and renal risks, in accordance with newly updated guidelines (Cardiovascular Diabetology)
2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial
These data show for the first time, to our knowledge, reversibility of the abnormal pancreas morphology of type 2 diabetes by weight loss-induced remission (The Lancet Diabetes & Endocrinology)
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
A once-weekly GLP-1RA was able to substitute for prandial insulin in 54% of people, substantially reducing the number of prandial insulin injections; glycemic control improved, with the added benefits of weight loss and less hypoglycemia in the GLP-1RA arm (Diabetes Care)
Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes
Synopsis of the 2020 American Diabetes Association’s Standards of Medical Care in Diabetes Clinical Guideline (Annals of Internal Medicine)
Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
GAD65-specific immunotherapy has a significant effect on C-peptide retention in individuals with recent-onset type 1 diabetes who have the DR3-DQ2 haplotype (Diabetologia)
Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study
URLi was compatible with insulin pump use with a safety profile similar to lispro (Diabetes Technology and Therapeutics)
Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes
we provide an overview of the mechanisms underlying the role of bile acids in glucose and lipid metabolism, as well as the occurrence and development of T2DM. Bile acid-targeted therapy may represent a valid approach for T2DM treatment (Journal of Diabetes Research)
Defining the Future of Endocrine Services in the UK
The Society for Endocrinology has set up a work stream called “Defining the Future of Endocrinology working group”, in the post Covid era (ABCD)
Treatment Options for MODY Patients: A Systematic Review of Literature
Our aim is to provide the reader with an easy-to-read update that can be used to drive the clinician’s therapeutical approach to these patients after the molecular diagnosis (Diabetes Therapy)
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
Timely insulin initiation may prevent diabetes progression, reduce diabetes-related complications and has less serious adverse effects (Diabetes Therapy)
Patient‐reported outcomes after 10‐year follow‐up of intensive, multifactorial treatment in individuals with screen‐detected type 2 diabetes: the ADDITION‐Europe trial
Intensive, multifactorial treatment of individuals with screen‐detected type 2 diabetes did not affect self‐reported health status, diabetes‐specific quality of life, or diabetes treatment satisfaction at 10‐year follow‐up compared to routine care (Diabetic Medicine)
The Australian response to the COVID-19 pandemic and diabetes – lessons learned
Once the COVID-19 pandemic is over, review of all the changes will be important, determining which should be permanently implemented. The learnings from COVID-19 should help prepare Australia for future pandemics or other major health crises (Diabetes Research and Clinical Practice)
Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis
At admission, combining procalcitonin and presence of fever may be of value to distinguish ketoacidosis patients with and without proven bacterial infection, admitted in intensive care unit (Annals of Intensive Care)
Outcomes in Patients With Hyperglycemia Affected by Covid-19: Can We Do More on Glycemic Control?
Insulin infusion may be an effective method for achieving glycemic targets and improving outcomes in patients with Covid-19 (Diabetes Care)
Hyperglycemia in Medically Critically Ill Patients: Risk Factors and Clinical Outcomes
In our high acuity medically critically ill patient population, achieving time-weighted average daily blood glucose levels <180mg/dl reliably while in the ICU significantly decreased the odds of subsequent hospital mortality. Suboptimal glycemic control during the ICU stay, on the other hand, significantly increased the odds of a longer-than-predicted ICU and hospital stay (American Journal of Medicine)
The Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial
The major benefits for patients with T2D in ADVANCE did not substantially differ across levels of baseline ASCVD risk and HbA1c (Diabetes Care)
- 1
- 2
- 3
- …
- 23
- Next Page »
Glycosmedia is also available as an App: